Australia's Clarity Pharma rises; Jefferies upgrades to 'buy' after latest trial
17/12/2025 03:45
Updates with share moves ** Shares of Australia's Clarity Pharmaceuticals CU6.AX rise as much as 14% to A$3.33, their biggest intraday pct gain since October 16 ** Jefferies upgrades rating on the clinical radio-pharmaceutical co to "buy" from "hold", retains A$5.00 price target ** Brokerage says Phase 2 trial data shows co's 64Cu-Sartate in patients with neuroendocrine tumours (NETs) identified more lesions than competition ** After CU6's share price performance, we move to 'buy' - Jefferies ** YTD, shares down 30% (Reporting by Nichiket Sunil in Bengaluru) ((Nichiket.Sunil@thomsonreuters.com))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial